Systemic lupus erythematosus is a chronic, multisystem, inflammatory, autoimmune disorder characterized by formation of autoantibodies directed against self-antigens and immune-complex formation.
It can be suspected when ≥2 organ systems are involved.
It is predominantly diagnosed in females of childbearing age, rarely diagnosed before 8 years old.
Clinical presentation varies in different patients and the disease activity varies over time in a single patient. Majority of patients have arthralgia of the hand.
Patients with systemic lupus erythematosus on hydroxychloroquine fare better, having lower mortality rates compared with those not using the drug, a study has shown. This survival benefit is further enhanced by treatment adherence.
Hydroxychloroquine (HCQ) inhibits the differentiation of Th17 cells and production of interleukin 17 (IL-17) both in vitro and in patients with systemic lupus erythematosus (SLE), a recent study has shown.
The selective T cell costimulation modulator abatacept drives a rapid improvement in proteinuria, which leads to earlier, sustained complete response compared with placebo in patients with active class III or IV lupus nephritis, although the rate of complete response is similar between groups, suggests a study presented at the EULAR 2018 Congress.
Roshini Claire Anthony speaks with Dr Annie Law, a consultant at the Department of Rheumatology & Immunology, Singapore General Hospital, on how primary care physicians can help in the management of systemic lupus erythematosus (SLE).
Short- and long-term renal outcomes improve with early renin–angiotensin–aldosterone system (RAAS) blockade with renin–angiotensin system inhibitors (RASI) in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study.
Ofatumumab appears to be effective and well-tolerated in the treatment of patients with long-standing systemic lupus erythematosus, offering an alternative to the B cell–depleting agent rituximab, according to a study.
It appears that the Patient Reported Outcomes Measurement Information System Global Health Short Form (PROMIS10), which requires less than 2 minutes to complete, is useable, reliable and can efficiently screen for impaired physical function, emotional distress and pain in outpatients with systemic lupus erythematosus (SLE), reports a study.
Belimumab appears to provide long-term benefits in patients with active systemic lupus erythematosus (SLE), reducing disease activity and prednisone usage while having low accrual of organ damage, according to data from the continuation phase of the multicentre BLISS-76 study from US.
Substituting diets high in carbohydrates with those high in monounsaturated fatty acids in the context of low saturated fatty acids do not appear to yield favourable effects on blood pressure, according to a meta-analysis.
Among obese and overweight adults with type 2 diabetes mellitus, women appear to be less likely than men to develop mild cognitive impairment, independent of traditional risk factors, a recent study has shown.